Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1433020 | 0.95 | ALDH1A1 (0.47) | KDM4EALDH1A1MAPK1TSHRPANK3 | |
| SCHEMBL365996 | 0.93 | TSHR (0.49) | KDM4EALDH1A1MAPK1TSHRPANK3 | |
| SCHEMBL3611548 | 0.93 | TSHR (0.49) | KDM4EALDH1A1MAPK1TSHRPANK3 | |
| SCHEMBL23048205 | 0.87 | HRH4 (0.45) | KDM4EALDH1A1PANK3MAPTUSP2 | |
| SCHEMBL3188491 | 0.82 | CHRNB2 (0.55) | KDM4EALDH1A1SMN1; SMN2USP2CHRNB2 | |
| SCHEMBL3621462 | 0.82 | ALDH1A1 (0.58) | KDM4EALDH1A1MAPK1TSHRPOLB | |
| SCHEMBL11359955 | 0.82 | MAPT (0.53) | KDM4EALDH1A1TSHRSMN1; SMN2MAPT | |
| SCHEMBL28554481 | 0.82 | KDM4E (0.41) | KDM4EALDH1A1MAPK1TSHRPANK3 | |
| SCHEMBL18488206 | 0.81 | ALDH1A1 (0.39) | KDM4EALDH1A1MAPK1TSHRPANK3 | |
| SCHEMBL3291868 | 0.80 | KDM4E (0.39) | KDM4EALDH1A1MAPK1PANK3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20230295159-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| CN-109053723-B | Sulfonamide derivatives and pharmaceutical use thereof | EA制药株式会社 | 2021-09-03 | — | — | CN | disclosed |
| US-20210188860-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2021-06-24 | — | — | US | disclosed |
| EP-3722284-A1 | 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2020-10-14 | — | — | EP | disclosed |
| EP-3402781-B1 | 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2020-03-04 | — | — | EP | disclosed |
| EP-3064491-B1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | EA PHARMA CO LTD (JP) | 2020-01-08 | — | — | EP | disclosed |
| US-20190106429-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2019-04-11 | — | — | US | disclosed |
| US-20150051395-A1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | AJINOMOTO CO., LTD. (JP) | 2015-02-19 | — | — | US | disclosed |
| US-8933072-B2 | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8895745-B2 | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-20130244993-A1 | SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| EP-2582698-A1 | SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE | Vitae Pharmaceuticals, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011159760-A1 | SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE | VITAE PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2011-07-28 | — | — | US | disclosed |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2011-07-28 | — | — | US | disclosed |
| WO-2011079133-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244993-A1 | SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE | CYP11B1, CYP11B2, HSD3B1 | KDM4E 2449/4885ALDH1A1 228/4885MAPK1 1597/4885 |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAPK7, MAPK14 | KDM4E 1166/4885ALDH1A1 4181/4885MAPK1 5/4885 |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | KDM4E 2919/4885ALDH1A1 337/4885MAPK1 2996/4885 |
| US-20230295159-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ATXN10, GCG, ATXN2L | KDM4E 1181/4885ALDH1A1 2764/4885MAPK1 1888/4885 |
| US-20150051395-A1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | ITGB4, ITGA4, ITGA2 | KDM4E 771/4885ALDH1A1 1151/4885MAPK1 3932/4885 |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | FGFR3, FGFR1, FGFR2 | KDM4E 928/4885ALDH1A1 1131/4885MAPK1 1167/4885 |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, NRAS | KDM4E 3625/4885ALDH1A1 1224/4885MAPK1 81/4885 |
| US-20210188860-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | KDM4E 2919/4885ALDH1A1 337/4885MAPK1 2996/4885 |
| US-20190106429-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | KDM4E 2919/4885ALDH1A1 337/4885MAPK1 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.